rs34248551
Variant summary
Our verdict is Benign. Variant got -14 ACMG points: 0P and 14B. BP4_StrongBP6_ModerateBS1BS2
The NM_012082.4(ZFPM2):āc.1871C>Gā(p.Ser624Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000682 in 1,613,896 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (ā ).
Frequency
Consequence
NM_012082.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ZFPM2 | NM_012082.4 | c.1871C>G | p.Ser624Cys | missense_variant | 8/8 | ENST00000407775.7 | NP_036214.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ZFPM2 | ENST00000407775.7 | c.1871C>G | p.Ser624Cys | missense_variant | 8/8 | 1 | NM_012082.4 | ENSP00000384179.2 |
Frequencies
GnomAD3 genomes AF: 0.000250 AC: 38AN: 152130Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000604 AC: 15AN: 248206Hom.: 0 AF XY: 0.0000520 AC XY: 7AN XY: 134688
GnomAD4 exome AF: 0.0000486 AC: 71AN: 1461648Hom.: 1 Cov.: 31 AF XY: 0.0000605 AC XY: 44AN XY: 727110
GnomAD4 genome AF: 0.000256 AC: 39AN: 152248Hom.: 0 Cov.: 32 AF XY: 0.000215 AC XY: 16AN XY: 74454
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 20, 2024 | The c.1871C>G (p.S624C) alteration is located in exon 8 (coding exon 8) of the ZFPM2 gene. This alteration results from a C to G substitution at nucleotide position 1871, causing the serine (S) at amino acid position 624 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The ZFPM2 p.Ser624Cys variant was not identified in the literature nor was it identified in LOVD 3.0. The variant was identified in dbSNP (ID: rs34248551) and ClinVar (classified as a VUS by Invitae). The variant was also identified in control databases in 24 of 279608 chromosomes at a frequency of 0.00008583 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: African in 21 of 24128 chromosomes (freq: 0.00087), Other in 2 of 7120 chromosomes (freq: 0.000281) and Latino in 1 of 35338 chromosomes (freq: 0.000028), but was not observed in the Ashkenazi Jewish, East Asian, European (Finnish), European (non-Finnish), and South Asian populations. The p.Ser624 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
46,XY sex reversal 9 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 23, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at